News

Today [9 May], Medicines Discovery Catapult and LifeArc, leading forces driving UK innovation in drug discovery, announce their strategic partnership.


The identification and development of novel biomarkers that detect efficacy and safety of novel drug molecules, which can be used in human trials, will be the focus of the partnership.

To support their ambitious growth plans, Dundee-based resourcing group Entrust Resource Solutions have acquired a second company, SCI Search and Selection, increasing their portfolio to three consultancies.

Arecor Limited (“Arecor” or “the Company”), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces dosing of the first patient in its Phase I clinical trial for its ultra-rapid acting insulin product candidate, AT247. 

Arecor Limited (“Arecor” or “the Company”), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology, ArestatTM to develop superior treatments for a range of disease areas, including diabetes, today announces that it has signed a collaboration with a new major global pharmaceutical partner.

Study compares two in vitro liver methods to determine which one best predicts BDIs

To view the May 2019 eNews click here


‘Pay as you go’ Artificial Intelligence


Chief.AI and Medicines Discovery Catapult awarded funding to make AI accessible to all drug discovery researchers


Today [1 May 2019], Artificial Intelligence (AI) in drug discovery gains further support as Chief.AI and Medicines Discovery Catapult secure a grant from Innovate UK to make AI accessible to all drug discovery researchers.


This partnership will address the need for more accessible AI and data in the B2B marketplace – prioritising drug discovery, diagnostics and clinical trials markets.

NEW YORK, NY & LONDON, UK, April 30th 2019 (Newswire) -- Alpha MD, a London-based global leader in healthcare research analytics and consulting, and Liberate Ideas, Inc. the leading provider of digital patient education for physicians, announce today a partnership agreement in order to initiate integration of Liberate Health in the UK’s National Health Service(NHS).

AMSBIO reports on how several leading European research groups have used their Lipidure® coated microplates to help culture physiologically functional, light-responsive retinal organoids.

Development of in vitro models of the human retina in which to perform pharmacological and toxicological studies is an urgent area of vital research. An essential step for developing in vitro models of human retina is the ability to generate laminated, physiologically functional, and light responsive retinal organoids from renewable and patient-specific sources.

Pages